Final Programme - iuphar

FC13 Maximising benefits and minimizing harms from
drugs
Wed 123 Effects of CYP4F2 genetic polymorphisms on warfarin dose requirements in Caucasian patients
initiating therapy
Veronique Michaud, (Canada), M Frappier, M Champagne, D Brouillette, D Roy, I Taillon, G O'Hara,
D Gossard, M Phillips, A Ajami, J Turgeon
Wed 124 Inhibition of human liver microsomal opioid glucuronidation by ketamine – A potential pharmacokinetic
drug-drug interaction
John Miners, (Australia), V Uchipichat, P Ruangrut, D Elliot, B Janchawee, A Evans
Wed 125 Estimation of creatinine clearance and gentamicin dose using lean body weight prediction
Sarah Mitchell, (Australia), S Hilmer, C Kirkpatrick, R Hansen, MF Singh
Wed 126 Estimation of lean body weight in older black and white men and women: the Health, Aging and Body
Composition Study
Sarah Mitchell, (Australia), C Kirkpatrick, A Newman, S Satterfield, A Schwartz, A Simonsick, S Hilmer
Wed 127 Influence of the VKORC1 genetic polymorphism and patient characteristics upon warfarin dose in
Japanese elderly patients
Jun Miura, (Japan), H Nakashima, T Tateishi
Wed 128 Relation between ethanol-induced oxidative stress and apoptosis in human hepatoma (SK-Hep-1) cells
Yoshiya Mochizuki, (Japan), M Tsuji, H Oyamada, M Ota, C Kurahashi, K Oguchi
Wed 129 Genotypic determinants of CYP2D6 activity and its clinical implications in Indo-Trinidadians
Lazara Montane Jaime, (Trinidad & Tobago), A Lalla
Wed 130 Making therapeutic drug monitoring of efavirenz work: what is a subtherapeutic concentration?
Emilia C Monteiro, (Portugal), U Caixas, I Germano, S Gouveia, A Carlos, TF Lampreia, T Branco,
SA Pereira
Wed 131 Effects of the Crotalus durissus cascavella venom on renal tubular cells
Janaina Monteiro, (Brazil), A Torres, R Menezes, F Monteiro, R Dantas, A Martins, H Monteiro
Wed 132 The development of a novel system for the investigation of microvascular dysfunction
E Moss, L Rankin, S Lynagh, David Bunton, (UK)
Wed 133 Variability of tamoxifen metabolism in vivo is influenced by genotypes of drug metabolizing enzymes
Thomas Mürdter, (Germany), W Schroth, H Brauch, M Eichelbaum, M Schwab
Wed 134 Frequency of adverse drug reactions type A and type B registered with intensive monitoring system
Snezana Mugosa, (Montenegro), Z Todorovic, N Duborija-Kovacevic
Wed 135 Spontaneous reporting of adverse drug reactions and level of intervention
Snezana Mugosa, (Montenegro), Z Todorovic, A Boskovic, N Duborija-Kovacevic
Wed 136 A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single dose efavirenz population
pharmacokinetics in Ugandans
Jackson K Mukonzo, (Uganda), D Röshammar, P Waako, M Andersson, T Fukasawa, L Milani,
J Ogwal-Okeng, L Gustafsson, E Aklillu
Wed 137 Using prescribing data to determine drug persistence for the purpose of pharmacovigilance
Isa Naina Mohamed, (UK), P Helms, C Simpson, J McLay
Wed 138 Metformin and lactic acidosis: Do we pay attention to the renal function in the elderly?
Makiko Nakagawa, (Sweden), U Bergman
254 Wednesday 21 July ■ 13:00 - 14:00 ■ Poster Area